Prelude Therapeutics (PRLD) IPO Opens 33% Higher

Today's IPO for Prelude Therapeutics Incorporated (NASDAQ: PRLD) opened for trading at $25.23 after pricing its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share.

In addition, Prelude Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,248,750 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Morgan Stanley, Goldman Sachs & Co. LLC and BofA Securities are acting as joint book-running managers for the offering.

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

You May Also Be Interested In

• Scribe Therapeutics files for proposed Nasdaq IPO
• Ares Acquisition Corporation III raises $395M in NYSE IPO
• EShallGo closes $750,000 registered direct offering at $1 per share